NewTimeSpace News,18 March,Singapore-based Ley Choon Group has announced that the effective date for its transfer of listing status from the Singapore Exchange Catalist to the Mainboard is 23 March 2026.
NewTimeSpace: MicroPort NeuroScientific Corporation (02172.HK) announced that its independently developed APOLLO Dream® Sirolimus Targeted Eluting Stent System has recently been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).It is the world’s first balloon-expandable, rapid-exchange drug-eluting stent in the neurointerventional field to receive this designation.
Since being included in the Stock Connect in March 2026, Qingsong Health (02661.HK) has seen strong share price gains. As of March 17, it closed at HK$126.6, up 458.20% from its IPO price, with a market cap of HK$26.13 billion. The company has successfully pivoted from insurance services to digital integrated health services, with the latter accounting for 76.7% of revenue in H1 2025. However, this transition has triggered a surge in costs, causing gross margin to plunge from 82.6% to 32.5%. Additionally, active users have dropped sharply from 71 million to 23 million, posing serious challenges to user retention and acquisition momentum.
NewTimeSpace News,On March 17, Singapore-listed Trendlines announced that the SEGER IDEA™ laparoscopic bowel closure device independently developed by its subsidiary Seger has successfully completed three first-in-human clinical trials in El Salvador.
NewTimeSpace News,On March 17, Singapore-listed Chasen Holdings announced that its wholly-owned subsidiary CLEE has entered into a share sale and purchase agreement with two vendors to acquire an additional 22.05% equity interest in RPT for S$632,974. Upon completion of the acquisition, Chasen’s shareholding ratio in RPT will rise to 77.05%.
NewTimeSpace News,On March 17, Singapore-listed Samudera Shipping Line announced that its Japanese subsidiary BOS has completed the acquisition and delivery of two container vessels.
NewTimeSpace News,On March 17, Singapore-listed Autagco Ltd. announced that it has entered into a share subscription agreement with Aurico and three independent subscribers, planning to issue up to 3 billion new ordinary shares to raise a total of approximately S$3 million, which will be used to improve the company's financial position, supplement working capital and fuel business expansion.
NewTimeSpace News,On March 17, Singapore-listed Sunrise Shares Holdings announced that it had received a listing and quotation notice from the Singapore Exchange (SGX), in relation to the proposed issuance of 34,482,800 consideration shares. This marks a major progress in its acquisition of the entire equity interest in Fuzhou Tianfujia Industrial Co., Ltd., with all preconditions for the acquisition having been satisfied.
NewTimeSpace News,On March 18, Singapore-listed Marco Polo Marine announced that its indirect subsidiary PKRO has won a 15-year charter contract for emergency towage and salvage services from Taiwan's Marine Port Bureau, with the contract valued at NT$2.948 billion (approximately S$118 million).
NewTimeSpace News,On March 18, Singapore-listed Olam Group announced that its wholly-owned subsidiary ofi, a global provider of natural food and beverage ingredients, has successfully secured its first dual-tranche syndicated loan totalling EUR 1.1 billion, with the proceeds to be used for refinancing ofi’s existing loans and general corporate purposes.
NewTimeSpace: Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (02566.HK) announced that its independently developed JY47 Injection has obtained implicit approval for clinical trials from the National Medical Products Administration (NMPA) of China. The drug is intended for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis.
Following a roughly 40% decline in early March, CF PharmTech (02652.HK) closed up 21.39% at HK$27.92 on March 16, 2026, spurred by positive catalysts. On March 13, the IND application for its inhalation dry powder ICF001 (for PAH and PH-ILD) was accepted by the NMPA, potentially filling a domestic void in PH-ILD treatment. While the company has 6 marketed products, its core product CF017 (Budesonide Inhalation) accounts for over 90% of revenue, leaving its risk-resistance structure fragile. The current TTM P/E of 384.57x reflects high market expectations for the innovation pipeline but also carries the risk of a valuation pullback.
NewTimeSpace News,On 16 March, Singapore-listed Stamford Land issued an announcement disclosing that its wholly-owned dormant Australian subsidiary SPS has been the subject of a winding-up petition filed by Parkview with the Supreme Court of New South Wales, Australia. Stamford Land stated that it does not intend to contest the petition, and the matter is not expected to have any material impact on the Group's operations and financial position.
NewTimeSpace News,On 16 March, Singapore-listed Geo Energy announced the completion of its proposed share placement, successfully issuing and placing 35 million new shares at a price of SGD0.425 per share. The placed shares are expected to start trading on the Mainboard of the Singapore Exchange on 18 March.
NewTimeSpace News,On 16 March, Hatten Land, a Singapore-listed company under judicial management, issued an announcement disclosing that it has used a portion of the loan under the facility agreement signed with Skyone to refinance its indebtedness under the previously entered secured facility agreement with Brilliant. Brilliant has executed a deed of discharge and release, formally terminating the relevant secured facility agreement and the assignment of receivables agreement.
NewTimeSpace News,On March 16, Singapore-listed GuocoLand announced that its wholly-owned subsidiary intends to grant an option to purchase a residential unit at River Modern to a connected person of one of the company's directors, with a transaction price of S$2.24 million.
